FRACTION (Fast Real-time Assessment of Combination Therapies in Immu no-Oncology)-gastric cancer (GC): A randomized, open-label, adaptive, phase 2 study of nivolumab in combination with other immuno-oncology (IO) agents in patients with advanced GC.
作者:
Denlinger, Crystal Shereen
Denlinger, Crystal Shereen
D O I:
10.1200/JCO.2017.35.15_suppl.TPS4137